Raleigh, NC, United States

Salix Pharmaceuticals

www.salix.com
Raleigh, NC, United States

Salix Pharmaceuticals, Inc. is a specialist American pharmaceutical company. It develops drugs and medical devices that prevent and treat various gastrointestinal disorders. It is listed in the Russell 2000 index. This company is listed as having the most revenue per employee by Bizjournals.com. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
Salix Pharmaceuticals and University of Chicago | Date: 2017-04-03

Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.


Patent
Salix Pharmaceuticals and University of Chicago | Date: 2017-08-23

Presented herein are methods for preventing or treating tumor growth, tumor metastasis and/or abnormal proliferation of tumor cells in a subject, wherein the methods involve administration of a pharmaceutical composition comprising methylnaltrexone. Also presented herein are methods for inhibiting or slowing the growth of a tumor in a subject, wherein the methods include selecting a subject who is a suitable candidate for treatment with methylnaltrexone, and administering a composition comprising methylnaltrexone to the subject.


Patent
Salix Pharmaceuticals | Date: 2016-11-03

The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin.


Patent
Salix Pharmaceuticals | Date: 2016-09-30

The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.


Patent
Salix Pharmaceuticals | Date: 2017-01-04

The present invention provides new methods and kits for treating IBS; treating IBS in females; treating IBS in older subjects; and treating IBS in non-white subjects.


Patent
Salix Pharmaceuticals | Date: 2017-05-03

The present invention provides new methods and kits for the retreatment of IBS. A method selects a subject having Irritable Bowel Syndrome (IBS) for retreatment with rifaximin, wherein the method includes identifying a subject previously treated with rifaximin who is a responder; and wherein the subject is currently in need of treatment of IBS.


Patent
Salix Pharmaceuticals | Date: 2016-07-18

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin. The instant application also provides methods for determining if a subject has a neurological condition or hepatic encephalopathy by determining the critical flicker frequency and/or the venous ammonia level of the subject at two or more time points. The invention further provides methods for treating these subjects.


Patent
Salix Pharmaceuticals | Date: 2016-12-30

The present invention provides new methods and kits for the retreatment of IBS.


Patent
Salix Pharmaceuticals | Date: 2017-03-15

The instant application provides methods of diagnosing and treating a subject having IBS. In certain embodiments, the methods also include diagnosing subjects who will respond to IBS treatment with rifaximin. The methods include determining the identity and prevalence of the bacterial community in the gastrointestinal (Gl) tract. In certain embodiments, the microbiome comprises the Gl tract microbiome. In certain embodiments, the microbiome comprises the Gl tract bacterial population. In certain embodiments, the microbiome comprises stool bacterial. The methods include analysis of the identity of the bacterial community in the gastrointestinal (Gl) microbiome to produce a profile of diversity of the bacterial communities.


Patent
Salix Pharmaceuticals | Date: 2016-02-01

The invention relates to formulations and dosage schedules of balsalazide. The invention further relates to methods of producing pharmaceutical formulations of balsalazide.

Loading Salix Pharmaceuticals collaborators
Loading Salix Pharmaceuticals collaborators